LOGIN  |  REGISTER
Chimerix

Latest Life Science Stock Financings

Ocumetics Technology Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million

May 24
Last Trade: 0.30 -0.005 -1.67

Calgary, Alberta – May 24, 2024 - TheNewswire.  Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the first tranche of the private placement of debentures previously announced by the Corporation on May 15, 2024. The Corporation has issued secured convertible debentures having an aggregate face value principal amount of $3,000,000 (the “Principal”)....Read more


Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing

May 23
Last Trade: 23.03 -0.45 -1.92

Financing includes participation from new and existing investors Strengthens balance sheet, with pro forma cash position of approximately $1.0 billion, extending expected financial runway into the second half of 2027 Supports ongoing advancement of pipeline with multiple clinical-stage precision-guided therapeutics CAMBRIDGE, England & BOSTON / May 23, 2024 / Business Wire / Bicycle Therapeutics plc (NASDAQ: BCYC), a...Read more


Genelux Announces Proposed Public Offering of Common Stock and Warrants

May 23
Last Trade: 2.62 -1.98 -43.04

WESTLAKE VILLAGE, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants. All shares of common stock and accompanying warrants are being offered by Genelux. In addition, Genelux expects to grant the underwriters a 30-day option to purchase up to...Read more


Rakovina Therapeutics Announces $1.5 million Non-Brokered Private Placement

May 23
Last Trade: 0.08 -0.005 -5.88

All monetary figures listed in Canadian Dollars. VANCOUVER, British Columbia, May 23, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the undertaking of a non-brokered Private Placement (the “Offering”) for gross proceeds of up to $1.5...Read more


Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline

May 22
Last Trade: 5.64 -0.37 -6.16

Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points Strengthens balance sheet with cash, cash equivalents and short-term investments of $310 million and extends cash runway into 2027 CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class...Read more


Cytokinetics Announces Proposed Public Offering of Common Stock

May 22
Last Trade: 48.30 -0.68 -1.39

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $500 million of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Cytokinetics expects to grant the underwriters a...Read more


Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 22
Last Trade: 0.21 0.03 16.98

ATLANTA, May 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced the closing of its previously announced public offering of 8,500,000 shares of its common stock at a public offering...Read more


HEALWELL AI Closes Upsized $20 Million Bought Deal Offering

May 22
Last Trade: 1.72 0.00 0.00

TORONTO, May 22, 2024 (GLOBE NEWSWIRE) -- HEALWELL AI INC. (“HEALWELL” or the “Company”) (TSX: AIDX) is pleased to announce today that it has closed its previously announced “bought deal” private placement offering and issued 14,815,000 units of the Company (the “Units”) at a price of $1.35 per Unit, for aggregate gross proceeds of $20,000,250 (the “Offering”). Dr. Alexander Dobranowski, CEO of HEALWELL commented, “In addition to...Read more


Biodexa Pharmaceuticals Announces $7 Million of Gross Proceeds from Warrant Exercises

May 22
Last Trade: 1.03 -0.07 -6.36

Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking Twice that Amount in Non-dilutive Grant Funding May 22, 2024- Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces $7 million of gross proceeds from the exercise of previously issued warrants and an agreement...Read more


Therma Bright Announces up to $1,000,000 Unit Offering

May 22
Last Trade: 0.02 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - May 22, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announces that it proposes to undertake a non-brokered private placement of up to 100,000,000 units priced at $0.01 per unit for total proceeds of $1,000,000 (the "Offering"). Each unit will be comprised...Read more


Nyxoah Announces Proposed Offering of Ordinary Shares

May 22
Last Trade: 8.50 0.17 2.04

Mont-Saint-Guibert, Belgium – May 22, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today the commencement of a proposed underwritten public offering in the United States, which may include shares sold in a private offering to...Read more


Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

May 21
Last Trade: 2.63 0.04 1.54

SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of an oversubscribed underwritten offering of 99,459,458 shares of its common stock, at a price of $1.85 per share, which includes the exercise in full by the...Read more


MyMD Pharmaceuticals Secures Strategic Investments

May 21
Last Trade: 2.00 0.00 0.00

Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front BALTIMORE / May 21, 2024 / Business Wire / MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced...Read more


LifeStance Health Announces Launch of Secondary Public Offering

May 21
Last Trade: 5.70 -0.10 -1.72

SCOTTSDALE, Ariz., May 21, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health care, today announced that certain stockholders of the Company (the “Selling Stockholders”) intend to offer 20,000,000 shares of LifeStance’s common stock, par value $0.01 per share (the “Common Stock”), pursuant to a shelf...Read more


GT Biopharma Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 21
Last Trade: 3.68 -0.22 -5.64

BRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a definitive securities purchase agreements for the purchase and sale of 740,000 shares of the Company’s common stock at a purchase price of $4.35 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company...Read more


Dyne Therapeutics Announces Proposed Public Offering of Common Stock

May 20
Last Trade: 31.22 -0.03 -0.10

WALTHAM, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to...Read more


BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

May 17
Last Trade: 1.44 0.01 0.70

PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced it has closed its previously announced registered direct offering with healthcare-focused institutional investors and a certain existing investor and...Read more


Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 17
Last Trade: 0.21 0.03 16.98

ATLANTA, May 17, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced that it intends to offer and sell up to $2.1 million in shares of its common stock in a public offering. All shares of...Read more


T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

May 17
Last Trade: 4.95 -0.21 -4.07

LEXINGTON, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 2,025,317 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 2,025,317 shares of common...Read more


Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

May 16
Last Trade: 4.16 0.17 4.26

BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 10,638,476 shares of its common stock at a public offering price of $4.70 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase...Read more


Marvel Biosciences Announces Private Placement

May 16
Last Trade: 0.11 0.00 0.00

Calgary, Alberta--(Newsfile Corp. - May 16, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce a proposed non-brokered private placement of up to 10,000,000 units (the "Units") at a price of $0.10 per Unit for gross proceeds of up to $1,000,000 (the "Offering"). Each Unit will be comprised of one common share in the...Read more


Ocumetics Technology Announces Offering of up to $4 million of Secured Convertible Debentures

May 15
Last Trade: 0.30 -0.005 -1.67

Calgary, Alberta – TheNewswire - May 15, 2024.  Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a non-brokered private placement of secured convertible debentures having an aggregate face value principal amount of up to $4,000,000 (the “Principal”).  The debentures will be subject to an original issue discount of 6%, resulting in net...Read more


Adaptimmune Therapeutics Secures up to $125 Million Debt Financing with Hercules Capital

May 15
Last Trade: 1.05 0.04 3.96

First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approval Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that it has entered into a $125 million five-year, term loan...Read more


T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

May 15
Last Trade: 4.95 -0.21 -4.07

LEXINGTON, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 2,025,317 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 2,025,317 shares of common stock and...Read more


Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

May 15
Last Trade: 4.16 0.17 4.26

BOSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. All of the shares of common stock and...Read more


Alzamend Neuro Announces Initial Closing of Private Placement

May 14
Last Trade: 0.60 0.0056 0.94

Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes ATLANTA / May 14, 2024 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive...Read more


RxSight Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

May 13
Last Trade: 61.15 0.56 0.92

ALISO VIEJO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc. (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it has closed its underwritten public offering of 2,053,571 shares of its common stock, at a price to the public of $56.00 per share, which includes the full exercise by the underwriters of their option to...Read more


MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

May 13
Last Trade: 0.96 -0.03 -2.54

Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKT GKCC, LLC joins as a new investor with Katie Chudnovsky appointed as a Board Observer NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf,...Read more


Tivic Health Systems Announces Closing of $4.0 Million Public Offering

May 13
Last Trade: 0.40 -0.0051 -1.24

SAN FRANCISCO / May 13, 2024 / Business Wire / Tivic Health® Systems, Inc. ("Tivic", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the closing of its previously announced public offering of an aggregate of 4,710,000 shares of its common stock, Series A warrants to purchase up to 4,710,000 shares of common stock and Series B warrants to purchase up to 7,065,000 shares of common...Read more


China Jo-Jo Drugstores Announces $2.74 Million Registered Direct Offering

May 10
Last Trade: 2.99 0.05 1.59

HANGZHOU, China, May 10, 2024 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that it has entered into definitive agreements with a number of investors providing for the issuance of 1.61 million ordinary shares, at a purchase...Read more


iTeos Therapeutics Announces $120 Million Registered Direct Offering

May 10
Last Trade: 17.68 0.14 0.80

Led by existing investors RA Capital Management and Boxer Capital Purchase price of $17.50 represents a premium of approximately 44% to last close Further strengthens balance sheet with pro forma cash position of $715 million, extending anticipated runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, May 10, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical...Read more


Spectral Medical Announces C$8.5 Million Bought Deal Convertible Note Financing

May 9
Last Trade: 0.49 -0.005 -1.02

TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (TSX:EDT) (the "Company" or "Spectral"), is pleased to announce that it has entered into an agreement with Paradigm Capital Inc. (the "Underwriter"), in connection with a bought deal private placement consisting of the sale of 9% convertible notes of the Company (the "Convertible Notes") at a price of US$1,000 per Convertible Note due on May 1, 2028 (the "Maturity Date") for...Read more


Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million

May 9
Last Trade: 0.60 0.0056 0.94

ATLANTA / May 09, 2024 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), announced today that it has entered into a Securities Purchase Agreement (the “Agreement”) with an...Read more


Optinose Announces $55 Million Registered Direct Offering

May 9
Last Trade: 1.11 -0.02 -1.77

Led by Nantahala Capital and The D. E. Shaw Group with participation from existing and new investors Post-offering cash balance of ~$100 million expected to fund operating plan through 2025 Company expects XHANCE net revenues to be between $85 to $95 million for full year 2024     YARDLEY, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose...Read more


Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS

May 9
Last Trade: 12.04 0.04 0.33

Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-owned subsidiary, Verona Pharma, Inc. (“VPI” and together with Verona Pharma, the “Company”), have entered into strategic financing agreements...Read more


Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution

May 8
Last Trade: 21.72 -0.09 -0.41

AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company”), a biotechnology company focused on Alzheimer’s disease, today announced total gross proceeds of over $125 million from cash-exercises of warrants that were previously distributed to its shareholders (the “Warrants”). Gross proceeds from the Warrants represents the issuance of approximately 5.7 million common shares at an effective price...Read more


Apollomics Announces Private Placement Financing and Addition to Board of Directors

May 8
Last Trade: 0.25 -0.01 -4.75

FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it entered into subscription agreements for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $6 million to the...Read more


RxSight Announces Proposed Public Offering of Common Stock

May 8
Last Trade: 61.15 0.56 0.92

ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering. In addition, RxSight expects to grant the...Read more


Ligand Pharmaceuticals and Agenus Enter Into $100 Million Royalty Financing Agreement

May 7
Last Trade: 86.40 1.49 1.75

Capital infusion will support botensilimab and balstilimab (BOT/BAL) clinical development, confirmatory Phase 3 trial, and launch readiness activities Ligand entitled to royalties and milestone payments on six Agenus-partnered programs as well as royalties on future global net sales generated by BOT/BAL Transaction allows for a syndication of up to an additional $125 million in capital JUPITER, Fla. and LEXINGTON, Mass. / May 07,...Read more


Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement

May 7
Last Trade: 2.82 -0.07 -2.42

IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it has entered into a securities purchase agreement with certain institutional and accredited healthcare investors for a private investment in public equity financing that is expected to result in gross proceeds of approximately $50 million, before deducting offering expenses. Pursuant to the terms of the securities...Read more


Ainos Raises $9 Million in Growth Capital with Existing Shareholder

May 7
Last Trade: 1.06 -0.20 -15.87

Proceeds for scaling up the company's VELDONA and AI Nose growth initiatives Convertible note convertible at $4.5 per share placed with existing shareholder SAN DIEGO, CA / ACCESSWIRE / May 7, 2024 / Ainos, Inc. (NASDAQ:AIMD) (NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative...Read more


Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

May 7
Last Trade: 0.92 -0.01 -1.52

Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer...Read more


Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

May 7
Last Trade: 4.91 -0.25 -4.84

Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has closed its previously announced private placement with an institutional investor for the purchase of 615,242 shares of common stock (or certain pre-funded...Read more


Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

May 7
Last Trade: 0.60 0.0056 0.94

ATLANTA / May 07, 2024 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), announced today that it has terminated its “at-the-market” equity offering program relating to sales of common...Read more


HEALWELL AI Announces Upsize of Bought Deal to Up to $20 Million

May 6
Last Trade: 1.72 0.00 0.00

TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- HEALWELL AI INC. (“HEALWELL” or the “Company”) (TSX: AIDX) is pleased to announce today that, due to strong demand, it has agreed with Clarus Securities Inc. (“Clarus”) and Eight Capital Corp. (“Eight”), as Co-Bookrunners and Co-Lead Underwriters (the “Co-Lead Underwriters”), on behalf of a syndicate of underwriters (collectively, the “Underwriters”), to increase the size of its previously...Read more


ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants

May 6
Last Trade: 3.68 0.04 1.10

LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.900 per share and, to certain investors who so choose in lieu of common shares, pre-funded warrants to purchase 8,163,265 common shares at a price of $4.812 per pre-funded warrant (being the offering price per common share...Read more


Plus Therapeutics Announces Private Placement Financing of up to $18 Million

May 6
Last Trade: 2.14 -0.02 -0.93

AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it has entered into a securities purchase agreement with new institutional investors and Company insiders to raise up to approximately $18...Read more


HEALWELL AI Announces $16 Million Bought Deal Private Placement

May 6
Last Trade: 1.72 0.00 0.00

TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- HEALWELL AI Inc. ("HEALWELL" or the "Company") (TSX: AIDX), a data science and AI company focused on preventative care, is pleased to announce that it has entered into an agreement pursuant to which Clarus Securities Inc. and Eight Capital, as lead underwriters and co-bookrunners, together with a syndicate of underwriters (collectively, the “Underwriters”), will purchase 11,851,900 units of the...Read more


Medicus Pharma Announces Closing of Private Placement of Convertible Notes

May 3
Last Trade: 1.95 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - May 3, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce that it has completed the first closing of its previously announced private placement (the "Private Placement") of 10.00% Unsecured Convertible Notes due 2025 (the "Notes"). The Company issued US$5,172,500 aggregate principal amount of Notes in the first closing, which was unbrokered. The Company may issue...Read more


Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million

May 3
Last Trade: 3.56 -0.10 -2.73

AUSTIN, Texas, May 03, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the closing of its previously announced underwritten registered direct offering priced at-the-market under Nasdaq rules of 4,273,505 shares of its...Read more


Context Therapeutics Announces $100 Million Private Placement

May 2
Last Trade: 2.00 0.05 2.56

Financing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into a securities purchase agreement with certain...Read more


Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon

May 2
Last Trade: 23.15 0.84 3.77

Use of proceeds to fund working capital needs stemming from Novocure’s anticipated launch in non-small cell lung cancer and settle, upon maturity, Novocure’s convertible notes ROOT, Switzerland / May 02, 2024 / Business Wire / Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The committed capital...Read more


Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

May 2
Last Trade: 2.05 0.00 0.00

BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it has closed its previously announced private placement for the purchase and sale of 4,968,945 shares of common stock (or pre-funded warrants in lieu thereof), series A warrants to...Read more


Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

May 2
Last Trade: 4.91 -0.25 -4.84

Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has entered into a definitive agreement with an institutional investor for the purchase of 615,242 shares of common stock (or certain pre-funded warrants in lieu...Read more


Mustang Bio Announces Closing of $4 Million Public Offering

May 2
Last Trade: 0.21 -0.0071 -3.27

WORCESTER, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers, today announced the closing of its previously announced public offering for the purchase and sale of an aggregate of 16,877,638 shares of its common...Read more


Soleno Therapeutics Announces Proposed Public Offering of Common Stock

May 2
Last Trade: 41.16 -0.01 -0.02

REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase an...Read more


TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering

May 1
Last Trade: 2.21 0.17 8.33

FORT WORTH, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the closing of its previously announced public offering of an aggregate of 1,665,219 shares of its common stock...Read more


MedX Health Announces Proposed Non-Brokered Private Placement to Raise up to $2,000,000 and Provides an Update on Amendment to Series I Convertible Notes

May 1
Last Trade: 0.08 0.00 0.00

MISSISSAUGA, Ontario / May 01, 2024 / Business Wire / MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it is proposing to raise up to $2,000,000 by way of a Non-Brokered Private Placement of up to 28,571,428 Units at $0.07 per Unit (“Unit”). A Price Reservation Form for this proposed placement was filed with the TSXV on April 19, 2024. Each Unit will be comprised of One (1) fully paid common share and One...Read more


TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives

April 30
Last Trade: 7.56 -1.98 -20.75

$25 million funded at close; up to $25 million of additional capital available at the Company’s option, based on the achievement of certain revenue thresholds Capital from the transaction is expected to support execution of strategic expansion and fuel continued growth Including the full funding of this facility, along with current cash and cash equivalents on hand, the Company expects its cash runway to extend through 2025 DENVER /...Read more


Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management

April 30
Last Trade: 2.36 0.02 0.85

TORONTO and HOUSTON, April 30, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA) (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, announced today the closing of its previously announced CA$20 million investment by RA Capital Management, a multi-stage investment manager based in Boston, MA, by way of a non-brokered...Read more


Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts

April 30
Last Trade: 0.44 -0.02 -4.09

$22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA will make upside-sharing milestone payments to Daré representing 50% of the future payments otherwise payable to XOMA Transaction allows Daré to focus on advancing Phase 3 first-in-category investigational products Ovaprene®, a potential first FDA-approved hormone-free intravaginal...Read more


Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering

April 30
Last Trade: 0.66 -0.02 -3.54

CRANFORD, N.J., April 30, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has closed its previously announced registered direct offering for the purchase of an aggregate of 21,428,574 shares of its common stock and accompanying warrants to...Read more


Nuwellis Announces Closing of $2.7 Million Public Offering

April 30
Last Trade: 0.25 0.03 13.27

MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced the closing of its previously announced public offering of 11,250,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 16,875,000 shares of its common stock...Read more


Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

April 30
Last Trade: 2.05 0.00 0.00

BERKELEY HEIGHTS, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 4,968,945 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to...Read more


Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

April 29
Last Trade: 3.62 0.00 0.00

MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 689,680 shares of the Company’s common stock. The...Read more


China Jo-Jo Drugstores Announces $1.53 Million Registered Direct Offering

April 29
Last Trade: 2.99 0.05 1.59

HANGZHOU, China, April 29, 2024 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that it has entered into definitive agreements with a number of investors providing for the issuance of 0.9 million ordinary shares, at a purchase price...Read more


Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management

April 26
Last Trade: 2.36 0.02 0.85

TORONTO and HOUSTON, April 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA) (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, today announced a CA$20 million investment by RA Capital Management, a multi-stage investment manager based in Boston, MA, by way of a non-brokered private placement...Read more


Citius Pharmaceuticals Announces $15 Million Registered Direct Offering

April 26
Last Trade: 0.66 -0.02 -3.54

CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 21,428,574 shares of its common stock and accompanying warrants to purchase up to an...Read more


Belite Bio Announces $25 Million Registered Direct Offering

April 25
Last Trade: 45.57 0.00 0.00

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has entered into a securities purchase agreement with an institutional investor, for the purchase and sale of up to an...Read more


Scilex Announces Closing of $15 Million Registered Direct Offering

April 25
Last Trade: 1.13 0.04 3.67

PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the closing of its previously announced registered direct offering of an aggregate of 15,000,000 shares of its common stock, par...Read more


INmune Bio Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

April 25
Last Trade: 10.11 -0.01 -0.10

Boca Raton, Florida, April 25, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced today that it has entered into definitive agreements for the sale and purchase of 986,000 shares of its common stock and warrants to purchase up to an aggregate of...Read more


Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants

April 25
Last Trade: 0.68 -0.02 -2.81

PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying common stock warrants to purchase shares of its common stock. All of the shares,...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB